To the Editor,

We would like to thank the authors of the letter for their interest and criticism about our 'Letter to the Editor,' published November 2014 issue in The Anatolian Journal of Cardiology ([@ref1]) for entitled "Peripartum cardiomyopathy associated with triplet pregnancy." Triplet pregnancy and peripartum cardiomyopathy (PPCM) are uncommon separately in clinical practice; thus, their coexistence is even less common. We performed a search in Pubmed/Medline, Scopus, and Türkiye Atıf Dizini using combinations of the following keywords: "triplet pregnancy," "peripartum cardiomyopathy," and "multiple gestations." We could not find any topic about them. One case ([@ref2]) that was mentioned by the authors was published in Bahrain Medical Bulletin. This journal is not indexed in the databases mentioned above. Therefore, we were unable to reach this information. We thank the authors for their notice and reminder. There may be some cases that were missed due to undetected mother deaths or undiagnosed patients on World-wide. Today, in vitro fertilization is gradually becoming more common. It shows that we can encounter such situations more frequently in the future due to multiple gestations. This association has been presented for the first time in this topic as a case report. In this respect, our publication is valuable. The authors stated that their study ([@ref3]) is the largest series of patients with PPCM in Turkey. In that study, while there were twin pregnancies, triplet pregnancies were not detected.

There are no standard, universally accepted guidelines for the management of PPCM. The treatment of patients with PPCM is similar to other forms of non-ischemic dilated cardiomyopathy. However, it must be individualized based on the patient's clinical presentation ([@ref3]). Prolactin may have adverse effects on the heart muscle by restricting its blood supply and causing cell death ([@ref4]). Although early studies suggest that bromocriptine may be beneficial in the treatment of PPCM, large double-blind randomized trials are essential to confirm the results of smaller studies ([@ref5]). More research is needed to determine its safety and efficacy. Also, there is no information about bromocriptine in the 2013 ACCF/AHA Guidelines for the Management of Heart Failure and 2012 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. If larger studies substantiate and it takes part in universally accepted guidelines with strong recommendations, bro-mocriptine can be administered safely. Our patient improved gradually with conventional treatment of heart failure. Therefore, no additional treatment was considered, like bromocriptine.

Today, there is no clear consensus on the appropriate duration of peripartum cardiomyopathy drug therapy. Biteker et al. ([@ref3]) published the results of 42 prospectively followed PPCM patients. Four patients showed delayed deterioration during the study period. The findings of late deterioration indicate the need for close follow-up, with periodic determination of cardiac function in women in whom medications are discontinued after complete recovery. The patient is still in our follow-up. It was about 1.5 years after diagnosis, and deterioration was not observed. Metoprolol, spironolactone, furosemide, and ramipril, all with oral use, were administered in the daily treatment of the patient in the first 6 months, as mentioned in our letter. Spironolactone and furosemide were stopped, and only 50 mg of metoprolol and 5 mg of ramipril were given to the patient after 6 months up to 1 year. We stopped all medications at 12 months after the diagnosis. Because we thought this cardiomyopathy was associated with pregnancy, the effects of pregnancy were loss completely, and the patient had a complete recovery. The authors suggest that ACE inhibitors and beta-blockers should be continued for at least 2 years after complete recovery. We take into consideration the authors' recommendations about the duration of therapy after complete recovery.
